{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T06:01:03Z","timestamp":1785045663476,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Cancer Prevention and Treatment Research Association","award":["KY202301020"],"award-info":[{"award-number":["KY202301020"]}]},{"name":"eijing Cancer Prevention and Treatment Research Association","award":["KY202501033"],"award-info":[{"award-number":["KY202501033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04498-z","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:28:00Z","timestamp":1785043680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysis"],"prefix":"10.1007","author":[{"given":"Wenxin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-6383","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"issue":"8","key":"4498_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","volume":"30","author":"J Vansteenkiste","year":"2019","unstructured":"Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019;30(8):1244\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdz175.","journal-title":"Ann Oncol"},{"key":"4498_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1063183","volume":"13","author":"WF Tang","year":"2023","unstructured":"Tang WF, Ye HY, Tang X, Su JW, Xu KM, Zhong WZ, et al. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: a new milestone. Front Oncol. 2023;13:1063183. https:\/\/doi.org\/10.3389\/fonc.2023.1063183.","journal-title":"Front Oncol"},{"issue":"7","key":"4498_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","volume":"19","author":"R Rami-Porta","year":"2024","unstructured":"Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The international association for the study of lung cancer lung cancer staging project: proposals for revision of the tnm stage groups in the forthcoming (ninth) edition of the tnm classification for lung cancer. J Thorac Oncol. 2024;19(7):1007\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2024.02.011.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"4498_CR4","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.13.9030.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4498_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"issue":"22","key":"4498_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"10308","key":"4498_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(21)02098-5.","journal-title":"Lancet"},{"issue":"21","key":"4498_CR8","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO-24-01681","volume":"43","author":"E Felip","year":"2025","unstructured":"Felip E, Altorki N, Zhou C, Valli\u00e8res E, Csoszi T, Vynnychenko IO, et al. Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial. J Clin Oncol. 2025;43(21):2343\u20139. https:\/\/doi.org\/10.1200\/JCO-24-01681.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4498_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O'Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(22)00518-6.","journal-title":"Lancet Oncol"},{"key":"4498_CR10","unstructured":"National comprehensive cancer network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines\u00ae) [Non-Small Cell LungCancer Version 8.2025 \u2014 August 15, 2025]. Accessed November 6, 2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"issue":"11","key":"4498_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020;31(11):1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"issue":"10","key":"4498_CR12","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830\u201340. https:\/\/doi.org\/10.1200\/JCO.22.02186.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4498_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2310532.","journal-title":"N Engl J Med"},{"issue":"8","key":"4498_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9(8):e002891. https:\/\/doi.org\/10.1136\/jitc-2021-002891.","journal-title":"J Immunother Cancer"},{"issue":"20","key":"4498_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"issue":"10","key":"4498_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007047","volume":"11","author":"C Zhou","year":"2023","unstructured":"Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, et al. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. J Immunother Cancer. 2023;11(10):e007047. https:\/\/doi.org\/10.1136\/jitc-2023-007047.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4498_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86. https:\/\/doi.org\/10.1186\/s40425-018-0398-7.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4498_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1189\/jlb.0212072","volume":"92","author":"VM Stoecklein","year":"2012","unstructured":"Stoecklein VM, Osuka A, Lederer JA. Trauma equals danger--damage control by the immune system. J Leukoc Biol. 2012;92(3):539\u201351. https:\/\/doi.org\/10.1189\/jlb.0212072.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"4498_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1067\/msy.2000.103498","volume":"127","author":"K Ogawa","year":"2000","unstructured":"Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, et al. Suppression of cellular immunity by surgical stress. Surgery. 2000;127(3):329\u201336. https:\/\/doi.org\/10.1067\/msy.2000.103498.","journal-title":"Surgery"},{"issue":"11","key":"4498_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00262-015-1740-2","volume":"64","author":"P Xu","year":"2015","unstructured":"Xu P, Zhang P, Sun Z, Wang Y, Chen J, Miao C. Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway. Cancer Immunol Immunother. 2015;64(11):1383\u201392. https:\/\/doi.org\/10.1007\/s00262-015-1740-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"4498_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","volume":"17","author":"P Matzner","year":"2020","unstructured":"Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol. 2020;17(5):313\u201326. https:\/\/doi.org\/10.1038\/s41571-019-0319-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"4498_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112903","volume":"141","author":"S Cui","year":"2024","unstructured":"Cui S, Wang N, Liang Y, Meng Y, Shu X, Kong F. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: a comprehensive review. Int Immunopharmacol. 2024;141:112903. https:\/\/doi.org\/10.1016\/j.intimp.2024.112903.","journal-title":"Int Immunopharmacol"},{"key":"4498_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.567978","volume":"11","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu S, Guo H, Li X, Zhao S, Wang Y, et al. The impact of programmed death-ligand 1 expression on the prognosis of early stage resected non-small cell lung cancer: a meta-analysis of literatures. Front Oncol. 2021;11:567978. https:\/\/doi.org\/10.3389\/fonc.2021.567978.","journal-title":"Front Oncol"},{"issue":"7","key":"4498_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1200\/JCO-25-01828","volume":"44","author":"GD Goss","year":"2026","unstructured":"Goss GD, Darling GE, Westeel V, Nakagawa K, Massut\u00ed B, Perrone F, et al. Adjuvant durvalumab in completely resected early-stage non\u2013small cell lung cancer. J Clin Oncol. 2026;44(7):553\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4498_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771\u201385. https:\/\/doi.org\/10.1038\/nrd.2016.139.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"4498_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 2022;42(9):828\u201347. https:\/\/doi.org\/10.1002\/cac2.12327.","journal-title":"Cancer Commun"},{"issue":"11","key":"4498_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113129","volume":"10","author":"E Pons-Tostivint","year":"2021","unstructured":"Pons-Tostivint E, Lugat A, Fontenau JF, Denis MG, Bennouna J. STK11\/LKB1 modulation of the immune response in lung cancer: from biology to therapeutic impact. Cells. 2021;10(11):3129. https:\/\/doi.org\/10.3390\/cells10113129.","journal-title":"Cells"},{"issue":"8","key":"4498_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764\u201374. https:\/\/doi.org\/10.1001\/jama.2019.11058.","journal-title":"JAMA"},{"key":"4498_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231225036","volume":"16","author":"J Chen","year":"2024","unstructured":"Chen J, Lu W, Chen M, Cai Z, Zhan P, Liu X, et al. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024;16:17588359231225036. https:\/\/doi.org\/10.1177\/17588359231225036.","journal-title":"Ther Adv Med Oncol"},{"key":"4498_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2602628","author":"YL Wu","year":"2026","unstructured":"Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, et al. Selpercatinib in early-stage RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2602628.","journal-title":"N Engl J Med"},{"key":"4498_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8590","author":"JM Lee","year":"2022","unstructured":"Lee JM, Awad MM, Saliba TR, Caro N, Banerjee H, Kelly K. Neoadjuvant and adjuvant capmatinib in resectable non\u2013small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS8590.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4498_CR32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.athoracsur.2025.04.016","volume":"120","author":"H Ding","year":"2025","unstructured":"Ding H, Tao B, Xu L, Jiang G, Wang H. Neoadjuvant immunochemotherapy for stage II-IIIB non-small cell lung cancer with mutations beyond EGFR 19del, L858R, and ALK rearrangement. Ann Thorac Surg. 2025;120(6):1052\u201361. https:\/\/doi.org\/10.1016\/j.athoracsur.2025.04.016.","journal-title":"Ann Thorac Surg"},{"issue":"12","key":"4498_CR33","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1007\/s00262-023-03560-x","volume":"72","author":"Z Shen","year":"2023","unstructured":"Shen Z, Teng M, Han L, Bian D, Zhang J, Zhu X, et al. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer. Cancer Immunol Immunother. 2023;72(12):4235\u201347. https:\/\/doi.org\/10.1007\/s00262-023-03560-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4498_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.21037\/tlcr-2025-60","volume":"14","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu J, Zhu L, Huang X, Ye J, Seetharamu N, et al. Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations. Transl Lung Cancer Res. 2025;14(2):538\u201351. https:\/\/doi.org\/10.21037\/tlcr-2025-60.","journal-title":"Transl Lung Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04498-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:28:01Z","timestamp":1785043681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":34,"alternative-id":["4498"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04498-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors denied potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics-Committee of Cancer Hospital, Chinese Academy of Medical Sciences (Ethics approval number: 25\/731\u20135678).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study and the use of anonymized data, the requirement for writteninformed consent was waived by the institution ethics commitee.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An exemption from informed consent was obtained because of the retrospective property.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No generative AI or AI-assisted technologies were used during the analysis and writing process.","order":6,"name":"Ethics","label":"AI disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}